Global Norepinephrine Drug Market Size, Share and Trends Analysis Report, By Application (Neurogenic Shock, Septic Shock, and Others) and By End-User (Hospitals, Private Clinics, and Ambulatory Surgery Centres) Forecast Period (2022-2028)

The global norepinephrine drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Norepinephrine, commonly known as noradrenaline, was developed in the US in 1946 and was licensed for medical use in 1950. The international nonproprietary name (INN) for norepinephrine is norepinephrine, and the British approved name for noradrenaline is noradrenaline (BAN). This drug is used to treat persons who have high blood pressure. Norepinephrine is an USFDA-approved medicine for controlling blood pressure in certain acute hypotensive situations, additionally, a possible adjuvant in the treatment of cardiac arrest with profound hypotension. This application of norepinephrine is expected to propel market growth during the forecast period. Aged people are more susceptible to low blood pressure, and the population of geriatric people is growing rapidly in both developed and emerging economies. Hypotension is more common as people get older due to blood flowing to the heart, muscles, and brain decreases, resulting in plaque build-up in blood vessels. As a result, future market demand for norepinephrine drugs is expected to be boosted by the growing geriatric population.

 

 

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

 

• In September 2021, Baxter International Inc. received approval for commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection from the USFDA. In adult patients with severe, acute hypotension, norepinephrine is used to raise blood pressure (low blood pressure). Baxter’s norepinephrine formulation comes in two strengths- 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL).
• In August 2021, Breckenridge Pharmaceutical, Inc. launched Rafarm S.A.’s Norepinephrine Bitartrate Injection, USP (generic for Levophed). Breckenridge will sell the medicine under its own label, with a strength of 4 mg/4 mL (1 mg/mL) in cartons of ten vials.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape– Pfizer Inc., Sanofi S.A., Mylan N.V., Novartis International AG, and Hikma Pharmaceuticals plc, among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Norepinephrine Drug Market Report by Segment

By Application

• Neurogenic Shock
• Septic Shock
• Others

By End-User

• Hospitals
• Private Clinics
• Ambulatory Surgery Centres
• Others

Global Norepinephrine Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa